Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP).

Publication date: Jul 11, 2023

The severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic causes a high burden of acute and long-term morbidity and mortality worldwide despite global efforts in containment, prophylaxis, and therapy. With unprecedented speed, the global scientific community has generated pivotal insights into the pathogen and the host response evoked by the infection. However, deeper characterization of the pathophysiology and pathology remains a high priority to reduce morbidity and mortality of coronavirus disease 2019 (COVID-19). NAPKON-HAP is a multi-centered prospective observational study with a long-term follow-up phase of up to 36 months post-SARS-CoV-2 infection. It constitutes a central platform for harmonized data and biospecimen for interdisciplinary characterization of acute SARS-CoV-2 infection and long-term outcomes of diverging disease severities of hospitalized patients. Primary outcome measures include clinical scores and quality of life assessment captured during hospitalization and at outpatient follow-up visits to assess acute and chronic morbidity. Secondary measures include results of biomolecular and immunological investigations and assessment of organ-specific involvement during and post-COVID-19 infection. NAPKON-HAP constitutes a national platform to provide accessibility and usability of the comprehensive data and biospecimen collection to global research. NAPKON-HAP establishes a platform with standardized high-resolution data and biospecimen collection of hospitalized COVID-19 patients of different disease severities in Germany. With this study, we will add significant scientific insights and provide high-quality data to aid researchers to investigate COVID-19 pathophysiology, pathology, and chronic morbidity.

Open Access PDF

Concepts Keywords
36months Coronavirus
Coronavirus COVID-19
Global Deep phenotyping
Organ Infectious disease
Pathology SARS-CoV-2


Type Source Name
disease MESH COVID-19
disease MESH morbidity
disease VO protocol
disease MESH severe acute respiratory syndrome
disease MESH causes
disease IDO pathogen
disease IDO host
disease MESH infection
pathway REACTOME SARS-CoV-2 Infection
disease IDO quality
disease VO organ
disease IDO pathogen host
drug DRUGBANK Esomeprazole
disease VO effective
disease VO vaccination
disease MESH critical illness
disease MESH acute respiratory distress syndrome
disease MESH complications
drug DRUGBANK Pentaerythritol tetranitrate
disease VO time
disease VO efficient
disease VO population
disease IDO blood
disease MESH pneumonia
disease VO vaccine
disease IDO history
drug DRUGBANK Trestolone
drug DRUGBANK Dimercaprol
disease MESH muscle strength
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Corticorelin
disease MESH chronic illness
disease IDO algorithm
drug DRUGBANK Edetic Acid
disease VO storage
disease VO NAP
drug DRUGBANK Coenzyme M
drug DRUGBANK Trihexyphenidyl
disease IDO process
disease MESH long COVID
drug DRUGBANK Fica
drug DRUGBANK Dexamethasone
disease VO report
disease MESH syndromes
disease MESH cardiovascular disease
disease MESH Infectious Diseases
disease IDO infectious disease

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *